Jiangsu QYuns Therapeutics Gets NMPA Green Light for CSU Treatment QX013N
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...
MicroPort MedBot’s Toumai Robot Gets EU Green Light for Broad Surgical Applications
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that its Toumai endoscopic surgery...
MicroPort CardioFlow Medtech’s AltaValve Receives FDA Breakthrough Designation for Mitral Regurgitation Treatment
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...
Laekna’s ActRIIA Monoclonal Antibody LAE102 Gets Green Light from China’s CDE for Obesity Treatment
Sino-US biotech firm Laekna has announced that it has received clinical trial approval from the...
Cancer Diagnostics Firm Mirxes Aims for USD 100 Million in Hong Kong IPO
Mirxes, a Singapore-based company specializing in cancer diagnostics, has refiled a draft prospectus with the...
Astellas Invests USD 90 Million in New US Facility to Boost Research and Commercialization
Japanese pharmaceutical company Astellas Pharma Inc. (TYO: 4503) has inaugurated a state-of-the-art laboratory and office...
Novo Nordisk’s Q1 2024 Global Sales Surge 24% YOY on Strength of GLP-1 Therapies
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) reported a substantial 24% year-on-year (YOY) increase in...
Zai Lab’s Q1 2024 Revenue Rises 43% YOY on Strong Product Launch and NRDL Inclusion
Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) has announced its financial results for the first...
BeiGene’s Q1 2024 Revenue Jumps 68% YOY on Strength of Brukinsa and Tislelizumab Sales
BeiGene, Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the...
Brii Biosciences’ BRII-835 Aims for Breakthrough Therapy Status in China for Chronic Hepatitis B
The Center for Drug Evaluation (CDE) website has indicated that Brii Biosciences Ltd (HKG: 2137),...
Jiangsu Hengrui Pharmaceuticals Advances HRS-5965 with NMPA Clinical Trial Approval for Glomerular Diseases
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has...
Organon’s Q1 2024 Revenues Rise 7% YOY, Women’s Health and Biosimilars Lead the Way
Organon (NYSE: OGN), a leading women’s health specialist, announced a 7% year-on-year increase in revenues...
Innovent Biologics’ Mazdutide Shows Superiority in Type 2 Diabetes Phase III Trial
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Blue Sail Medical’s New Catheter Receives NMPA Approval for Complex Coronary Lesion Treatment
China’s Blue Sail Medical Co., Ltd (SHE: 002382) has received marketing approval from the National...
Abbisko and Allist Pharmaceuticals Initiate Phase II Trial for NSCLC Drug Combination
Abbisko Therapeutics Co., Ltd (HKG: 2256) and Allist Pharmaceuticals Co., Ltd have announced the upcoming...
Profluent’s Neural Network Model Designs High-Efficiency CRISPR Gene-Editing System
Biotechnology company Profluent has announced a significant advancement in the field of gene editing with...
Boehringer Ingelheim’s Anti-Sema3A BI 764524 Shows Promise in Diabetic Macular Ischemia Trial
Boehringer Ingelheim (BI) has announced the publication of results from a Phase I/IIa clinical trial...
Pfizer Pauses Dosing in DMD Gene Therapy Trial Following Participant’s Sudden Death
This week, Pfizer Inc. (NYSE: PFE) announced the unfortunate sudden death of a participant in...
Tonghua Dongbao Pharmaceuticals Inks Licensing Deal for Semaglutide in China
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a licensing agreement...
J&J’s Erleada Plus ADT Shows 0% Biochemical Recurrence Rate in High-Risk Prostate Cancer Trial
Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Phase II clinical trial for...